At H3 Biomedicine, drug discovery starts with the patient. With deep expertise in the genetics of cancer, we mine the large cache of publicly available cancer genomics data. Our scientists work outward from genetically defined populations to identify or to confirm therapeutic targets. Our discovery teams then apply the latest chemical synthesis and cell-based screening methods to rapidly classify and develop libraries of small molecules that interact with those targets. They also seek to develop biomarkers to facilitate patient identification and clinical testing. This disciplined method promises to produce a steady stream of novel anti-cancer compounds against targets that have not yet been "druggable."